Chih-Hsiang Lin ¹ Chen-Jui Ho ¹ Shih-Ying Chen ¹ Yan-Ting Lu ¹ Meng-Han Tsai ^1,2,3*

• ¹ Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
• ² School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan
• ³ Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital,, Kaohsiung, Taiwan

Antiseizure medications (ASMs) play a central role in seizure management, however, unpredictability in the response to treatment persists, even among patients with similar seizure manifestations and clinical backgrounds. An objective biomarker capable of reliably predicting the response to ASMs would profoundly impact epilepsy treatment. Presently, clinicians rely on a trial-and-error approach when selecting ASMs, a time-consuming process that can result in delays in receiving alternative non-pharmacological therapies such as a ketogenetic diet, epilepsy surgery, and neuromodulation therapies. Pharmacogenetic studies investigating the correlation between ASMs and genetic variants regarding their mechanistic targets offer promise in predicting the response to treatment. Sodium channel subunit genes have been extensively studied along with other ion channels and receptors as targets, however, the results have been conflicting, possibly due to methodological disparities including inconsistent definitions of drug response, variations in ASM combinations, and diversity of genetic variants/genes studied. Nonetheless, these studies underscore the potential effect of genetic variants on the mechanism of ASMs and consequently the prediction of treatment response. Recent advances in sequencing technology have led to the generation of large genetic datasets, which may be able to enhance the predictive accuracy of the response to ASMs.